# Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer

Source: https://onco.cc/trials/nct06491472/  
OnCo record `nct06491472` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ivonescimab, gemcitabine and nab-paclitaxel in pancreatic cancer, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, now recruiting.

## Summary

Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer is a phase 2, interventional study registered as NCT06491472 by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, with a registry enrolment figure of 36 participants, started 2024-07-15 and due to reach its primary completion in 2026-07-15. Interventions recorded: Ivonescimab; Gemcitabine; Nab paclitaxel; SBRT. Conditions listed: Pancreatic Cancer. Primary outcome: Objective Response Rate(ORR). Pancreatic eligibility wording from the registry: "* Histologically- or cytologically-confirmed diagnosis of pancreatic ductal adenocarcinoma (including adenosquamous carcinoma)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06491472
- Phase: 2
- Setting: Efficacy and Safety of Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer：A Single-arm, Open-label, Phase II Clinical Study
- Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT06491472: https://clinicaltrials.gov/study/NCT06491472

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06491472.json